AI Article Synopsis
- The study aimed to assess how common elevated intraocular pressure (IOP) and secondary glaucoma are in patients with herpetic anterior uveitis (AU) and identify related risk factors.
- Patients with herpetic AU treated at a specific medical center from 2001 to 2013 were analyzed, revealing that 75% experienced elevated IOP, with 15% developing glaucoma, often linked to higher IOP peaks.
- The findings suggest a significant association between pre-existing elevated IOP at the onset of uveitis and the development of glaucoma, indicating a need for further research into preventive treatments.
Article Abstract
Purpose: To determine the incidence of elevated intraocular pressure (IOP) and secondary glaucoma in herpetic anterior uveitis (AU), owing to either herpes simplex or varicella zoster virus, by using the Standardization of Uveitis Nomenclature (SUN) criteria, and to identify risk factors for the development of glaucoma.
Design: Retrospective observational cohort study.
Methods: Patients with herpetic AU presenting themselves between 2001 and 2013 at the ophthalmology department of the University Medical Center Groningen were included. Main outcome measures were the incidence of elevated IOP and glaucoma and risk factors for the development of glaucoma.
Results: Seventy-three herpetic AU patients were included. Ocular complications most commonly seen during follow-up for uveitis were elevated IOP (75%), keratitis (59%), dry eyes (34%), posterior synechiae (34%), cataract (32%), and glaucoma (15%). Glaucoma patients, in comparison to non-glaucoma patients, had a higher number of IOP peaks during their follow-up for uveitis (P < .001). The majority of patients with elevated IOP (91%) had this already at the start of the uveitis. Nineteen percent of the patients needed glaucoma surgery.
Conclusions: Using the SUN criteria, our study confirmed that elevated IOP and secondary glaucoma are major complications in herpetic AU. If an elevated IOP occurred, it was usually already present at the start of a uveitis episode. A risk factor for the development of glaucoma was the number of endured IOP peaks. Future studies are needed to evaluate whether early and prolonged use of antiviral and IOP-lowering medication may prevent glaucoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajo.2017.06.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corneal Confocal and Specular Microscopic Characteristics in Primary Open-Angle Glaucoma: An Optical Coherence Tomography (OCT)-Based Case-Control Study.
Cureus
December 2024
Cornea and Refractive Surgery, Al-Shifa Trust Eye Hospital, Rawalpindi, PAK.
Background: Glaucoma, particularly open-angle glaucoma (OAG), is a leading cause of irreversible blindness, associated with optic nerve damage, retinal ganglion cell death, and visual field defects. Corneal biomechanical properties and cellular components, such as corneal nerve and keratocyte densities assessed by in vivo confocal microscopy (IVCM), may serve as biomarkers for glaucoma progression. This study aimed to explore the relationship between corneal nerve parameters, keratocyte density, and optical coherence tomography (OCT)-derived retinal nerve fiber layer (RNFL) thickness in primary open-angle glaucoma (POAG) patients and controls.
View Article and Find Full Text PDFShort-Term Safety and Efficacy of PreserFlo™ Microshunt in Patients with Refractory Intraocular Pressure Elevation After Dexamethasone Implant Intravitreal Injection.
J Clin Med
January 2025
Department of Ophthalmology, University of Bonn, 53127 Bonn, Germany.
: The PreserFlo™ MicroShunt (PFMS) is a bleb-forming device considered to be less invasive than traditional glaucoma surgery such as trabeculectomy. This study evaluates the 1-year success rates as well as safety profile of PFMS in patients having high intraocular pressure (IOP) and/or glaucoma refractory to drop therapy with a history of prior intravitreal dexamethasone therapy. : A total of 16 eyes after PFMS implantation due to elevated IOP after intravitreal dexamethasone implant (DEX-I) administration were included in this retrospective cohort study.
View Article and Find Full Text PDFDevelopment and Evaluation of Polymethacrylate-Based Ophthalmic Nanofiber Inserts Containing Dual Drug-Loaded Dorzolamide and Timolol: In Vivo Study in Rabbit's Eye.
Biomedicines
January 2025
School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.
The aim of the study was to create a nanofiber insert incorporating Timolol (TIM) and Dorzolamide (DOR), targeting the management of glaucoma. This condition encompasses a variety of chronic, advancing ocular disorders typically associated with elevated intraocular pressure (IOP). The insert was made of Eudragite RL100 (EUD) polymer, a biocompatible material with high bioavailability, using the electrospinning method.
View Article and Find Full Text PDFNon-invasive fundoscopy as a tool to estimate intracranial pressure: a large animal model.
Acta Neurochir (Wien)
January 2025
Department of Neurosurgery, Odense University Hospital, Odense, Denmark.
Purpose: Intracranial pressure (ICP) monitoring is in most studies considered essential in avoiding secondary brain injury in patients with intracranial pathologies. Invasive monitoring of ICP is accurate but is unavailable in many clinical and prehospital settings. Non-invasive modalities have historically been difficult to implement clinically.
View Article and Find Full Text PDFCorneal Stromal Stem Cell-Derived Extracellular Vesicles Attenuate ANGPTL7 Expression in the Human Trabecular Meshwork.
Transl Vis Sci Technol
January 2025
Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Purpose: Regulating intraocular pressure (IOP), mainly via the trabecular meshwork (TM), is critical in developing glaucoma. Whereas current treatments aim to lower IOP, directly targeting the dysfunctional TM tissue for therapeutic intervention has proven challenging. In our study, we utilized Dexamethasone (Dex)-treated TM cells as a model to investigate how extracellular vesicles (EVs) from immortalized corneal stromal stem cells (imCSSCs) could influence ANGPTL7 and MYOC genes expression within TM cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!